Pulmonary hypertension owing to lung disease and/or hypoxia

This study tests whether the drug telaglenastat, taken twice daily for 12 weeks, can safely lower blood pressure in the lungs and improve heart and lung function in adults with pulmonary hypertension. About 28 participants will receive the drug on top of their usual care. The mai…

This study tests whether a 12-week program of moderate aerobic exercise and inspiratory muscle training can improve breathing, exercise capacity, and quality of life in people with pulmonary hypertension caused by lung disease. Participants will walk on a treadmill and use a brea…

This Phase 2 trial tests an oral drug called NS-863 in 177 adults with pulmonary hypertension linked to interstitial lung disease (PH-ILD). Participants will receive either a low dose, high dose, or placebo for 24 weeks. The main goal is to see if the drug improves blood vessel r…

This study looks at whether the inhaled drug iloprost can safely lower blood pressure in the lungs and improve exercise ability in adults with severe COPD. Fifteen participants will take iloprost 6 to 9 times daily for 12 weeks, with tests before and after treatment. There is no …